

# 2012 UCSF Breast Oncology Program Scientific Retreat

	Thursday, February 2
12:00	Atrium  Registration and Based Lunch
	Registration and Boxed Lunch
12:30-4:30	Kanbar Hall
12:30-12:40	Welcome and Introduction to Agenda and Program Status Laura van 't Veer, PhD, Program Leader, UCSF Breast Oncology Program
Heterogeneit	y of Response: Reversing Therapy Resistance (Moderator: Hope Rugo, MD)
12:40-1:10	Targeting the HER Pathway for Optimal Therapy Kent Osborne, MD
1:10-1:20	Q&A
1:20-1:40	Epigenetic Modulation in Hormone Therapy Resistance Pamela Munster, MD
1:40-1:50	Q&A
1:50-2:10	Spatial Systems Biology Joe Gray, PhD
2:10-2:20	Q&A
2:20-2:30	Controversies from the Moderator Perspective Hope Rugo, MD
2:30-2:50	<u>Break</u>
Physical Scient	ences and Oncology Center: Tissue Tension in High Risk Women (Moderator: Valerie Weaver, PhD)
2:50-3:10	Tissue Tension in Breast Cancer Jan Liphardt, PhD
3:10-3:20	Q&A
3:20-3:40	Good Breast Gone Bad: Activation of IL6/Akt Signaling Networks in High-Risk African American Women Victoria Seewaldt, MD
3:40-3:50	Q&A Tissue Board Determinants of Broost Concer Bisks Translational Opportunities for Broost Concer
3:50-4:10	Tissue-Based Determinants of Breast Cancer Risk: Translational Opportunities for Breast Cancer Prevention  E. Shelley Hwang, MD
4:10-4:20	Q&A
4:20-4:30	Controversies from the Patient Perspective Susan Samson
4:30-6:30	<u>Atrium</u>
	Poster Session and Reception
	(Light refreshments and beverages will be served.)
0.20 0.00	Friday, February 3
8:30-9:00	Atrium Registration & Continental Breakfast
9:00-5:00	Kanbar Hall
9:00-9:05	Welcome & Introduction Laura van 't Veer, PhD, Program Leader, UCSF Breast Oncology Program
Microenviron	ment and Immune System (Moderator: Zena Werb, PhD)
9:05-9:25	Enhancing Efficacy of Chemotherapy in Breast Cancer by Targeting Macrophages Lisa Coussens, PhD
9:25-9:35	Q&A
9:35-9:55	Translating Laboratory Science to the Clinic: A Novel Phase I/II Trial Targeting Macrophages in Triple Negative Breast Cancer
O.EE 40.05	Hope Rugo, MD
9:55-10:05	Q&A



# 2012 UCSF Breast Oncology Program Scientific Retreat

10:05-10:25	Immunogenicity, immunogenic cell death and response to therapy Michael Campbell, PhD
10:25-10:35	Q&A
10:35-10:45	Controversies from the Patient Perspective Carol Simmons
10:45-11:05	<u>Break</u>
	sion Session (Moderator: John Park, MD)
11:05-11:15	Presentation of Awards Hope Rugo, MD and Laura van 't Veer, PhD
11:15-11:25	Early Detection and Prevention Poster TBA [top poster selected by committee]
11:25-11:35	Epidemiology and Population Science Poster TBA [top poster selected by committee]
11:35-11:45 11:45-11:55	Discussant: Elad Ziv, MD
	General Discussion and Audience Questions
11:55-12:05	Physical Science TBA [top poster selected by committee]
12:05-12:15	Molecular Biology Poster TBA [top poster selected by committee]
12:15-12:25	Therapeutics and Clinical Trials Poster
	TBA [top poster selected by committee]
12:25-12:35 12:35-12:45	Discussant: Mark Moasser, MD General Discussion and Audience Questions
12.00 12.40	General Discussion and Addience Questions
10.45 1.45	Lymph
12:45-1:15	<u>Lunch</u>
Athena Breas	t Health Network and Care Efficiency (Moderator: Michelle Melisko, MD)
	t Health Network and Care Efficiency (Moderator: Michelle Melisko, MD)  Patient Reported Outcomes
Athena Breas	t Health Network and Care Efficiency (Moderator: Michelle Melisko, MD)  Patient Reported Outcomes  Linda Vincent
Athena Breas 1:15-1:25 1:25-1:45	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A
Athena Breas 1:15-1:25 1:25-1:45	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55 2:55-3:05	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A Athena at UCSF Laura van 't Veer, PhD Q&A
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A Athena at UCSF Laura van 't Veer, PhD
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55 2:55-3:05 3:05-3:25 3:25-3:35	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A Athena at UCSF Laura van 't Veer, PhD Q&A Personalized Risk Assessment and Decision Support Elissa Ozanne, PhD Q&A
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55 2:55-3:05 3:05-3:25	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A Athena at UCSF Laura van 't Veer, PhD Q&A Personalized Risk Assessment and Decision Support Elissa Ozanne, PhD Q&A Pathology Harmonization Project
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55 2:55-3:05 3:05-3:25 3:25-3:35 3:35-3:55	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A Athena at UCSF Laura van 't Veer, PhD Q&A Personalized Risk Assessment and Decision Support Elissa Ozanne, PhD Q&A
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55 2:55-3:05 3:05-3:25 3:25-3:35	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A Athena at UCSF Laura van 't Veer, PhD Q&A Personalized Risk Assessment and Decision Support Elissa Ozanne, PhD Q&A Pathology Harmonization Project Yunn-Yi Chen, MD, PhD and Ronald Balassanian, MD
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55 2:55-3:05 3:05-3:25 3:25-3:35 3:35-3:55 3:55-4:05 4:05-4:25	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A Athena at UCSF Laura van 't Veer, PhD Q&A Personalized Risk Assessment and Decision Support Elissa Ozanne, PhD Q&A Pathology Harmonization Project Yunn-Yi Chen, MD, PhD and Ronald Balassanian, MD Q&A Breast Cancer and the Environment Robert Hiatt, MD, PhD
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55 2:55-3:05 3:05-3:25 3:25-3:35 3:35-3:55 3:55-4:05	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A Athena at UCSF Laura van 't Veer, PhD Q&A Personalized Risk Assessment and Decision Support Elissa Ozanne, PhD Q&A Pathology Harmonization Project Yunn-Yi Chen, MD, PhD and Ronald Balassanian, MD Q&A Breast Cancer and the Environment
Athena Breas 1:15-1:25 1:25-1:45 1:45-1:55 1:55-2:25 2:25-2:35 2:35-2:55 2:55-3:05 3:05-3:25 3:25-3:35 3:35-3:55 3:55-4:05 4:05-4:25	Patient Reported Outcomes Linda Vincent Athena: A new Paradigm for Clinical Care and Research Laura Esserman, MD, MBA Q&A New Public-Private Interfaces for Advancing Life Sciences Research, Medicine and Health Keith Yamamoto, PhD Q&A Athena at UCSF Laura van 't Veer, PhD Q&A Personalized Risk Assessment and Decision Support Elissa Ozanne, PhD Q&A Pathology Harmonization Project Yunn-Yi Chen, MD, PhD and Ronald Balassanian, MD Q&A Breast Cancer and the Environment Robert Hiatt, MD, PhD

## **Faculty List**

#### Ronald Balassanian, MD

Assistant Professor, Department of Pathology, UCSF

## Michael Campbell, PhD

Assistant Professor, Department of Surgery, UCSF

# Yunn-Yi Chen, MD, PhD

Professor of Clinical Pathology, Director of Immunohistochemistry Laboratory, Department of Pathology, UCSF

#### Lisa Coussens, PhD

Chair of the Department of Cell & Developmental Biology; Director of Basic Research in the OHSU Knight Cancer Institute; Hildegard Lamfrom Chair in Basic Science, Oregon Health & Science University (OHSU)

#### Laura Esserman, MD, MBA

Professor, Departments of Surgery and Radiology, UCSF; Affiliate Faculty, Institute for Health Policy Studies, UCSF; Director, Carol Franc Buck Breast Care Center; Co-Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center

#### Joe Gray, PhD

Gordon Moore Professor and Chair, Biomedical Engineering, Oregon Health and Science University (OHSU); Director, OHSU Center for Spatial Systems Biomedicine; Emeritus Professor, UCSF, and Visiting Faculty, Lawrence Berkeley National Laboratory; Co-Director, Breast Cancer SPORE

#### Robert Hiatt, MD, PhD

Professor and Chair, Department of Epidemiology and Biostatistics, UCSF; Director of Population Sciences and Deputy Director, UCSF Helen Diller Family Comprehensive Cancer Center

## E. Shelley Hwang, MD, MPH

Professor of Surgery, Chief, Breast Surgery, Duke University

#### Karla Kerlikowske, MD

Professor, Departments of Medicine and Epidemiology/Biostatistics, UCSF

## Jan Liphardt, PhD

Associate Professor of Physics at UC Berkeley; Director Bay Area Physical Science-Oncology Center

## Michelle Melisko, MD

Associate Clinical Professor, Department of Medicine, UCSF

#### Mark Moasser, MD

Professor, Department of Medicine (Hematology/Oncology), UCSF

#### Pamela Munster, MD

Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Program and Associate Director, Investigational Therapeutics, UCSF Helen Diller Family Comprehensive Cancer Center

## Kent Osborne, MD

Professor, Departments of Medicine, and Cellular and Structural Biology; Director, Baylor Cancer Center; Director, Breast Center at Baylor College of Medicine

## Elissa Ozanne, PhD

Assistant Professor, Department of Surgery and Institute for Health Policy Studies, UCSF

#### John Park, MD

Professor, Departments of Medicine and Neurological Surgery; Co-Director, Bay Area Breast Cancer SPORE, UCSF

#### Hope Rugo, MD

Clinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education, UCSF

# Susan Samson

Bay Area Breast Cancer SPORE advocate

## Victoria Seewaldt, MD

Professor of Medicine, Duke University; Leader Duke University Comprehensive Cancer Breast and Ovarian Cancer Program

## **Carol Simmons**

Bay Area Breast Cancer SPORE advocate

# Laura van 't Veer, PhD

Professor, Department of Laboratory Medicine, UCSF; Leader, Breast Oncology Program; Director, Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center; Principal Investigator, Breast SPORE; Angela and Shu Kai Chan Endowed Chair in Cancer Research, UCSF

## **Linda Vincent**

Bay Area Breast Cancer SPORE advocate

#### Valerie Weaver, PhD

Associate Professor, Departments of Surgery and Bioengineering and Therapeutics; Director, Center for Bioengineering and Tissue Regeneration, UCSF

# Zena Werb, PhD

Professor and Vice-Chair, Department of Anatomy, UCSF

## Keith Yamamoto, PhD

Executive Vice Dean, School of Medicine; Professor, Departments of Cellular/Molecular Pharmacology and Biochemistry/Biophysics, UCSF

# Elad Ziv, MD

Associate Professor, Department of Medicine, UCSF